Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia

Alexis A. Thompson*, Jeaniene A. Talley, Ha Nancy Do, H. Lee Kagan, Lori Kunkel, James Berenson, Max D. Cooper, Andrew Saxon, Randolph Wall

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


Leukemic B cells in chronic lymphocytic leukemia (B-CLL) typically exhibit low or undetectable surface lg. Because the 829 (CD79b and Igβ) and mb-1 (CD79a and Igα) gene products are required for surface Ig display in the B-cell receptor complex (BCR), we analyzed the expression of these genes in B-CLL cells. The majority (83%) of the randomly selected B-CLL patient samples analyzed exhibited low or undetectabe surface BCR measured by μ heavy chain and B29 expression. Levels of mb-1 mRNA in these B-CLL samples with low surface BCR were similar to those in normal B cells. Among those with decreased surface expression, B29 mRNA was not detected in half of these B-CLL samples. The remaining B-CLL samples with diminished surface BCR contained normal levels of B29 mRNA. Further analysis of cDNA clones from the majority of these latter samples contained point mutations, insertions, or deletions that were largely located in the B29 transmembrane and cytoplasmic domains. These results indicate the occurrence of somatic mutations predicted to affect B29 expression and/or function in the majority of B-CLL and suggest that these aberrations underlie the diminished surface BCR display and loss of BCR signaling characteristic of this leukemia.

Original languageEnglish (US)
Pages (from-to)1387-1394
Number of pages8
Issue number4
StatePublished - Aug 15 1997

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this